Here is another example of how therapy advances against blood cancers–leukemia, lymphoma and multiple myeloma–lead the way in today’s war against cancer:
FDA Okays New First-Line Therapy for Rare Leukemia
By Cole Petrochko, Staff Writer, MedPage Today
Published: June 19, 2010
WASHINGTON — The FDA has approved nilotinib (Tasigna) as first-line therapy of the rare blood and bone marrow disorder Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML).
Nilotinib was approved in 2007 for treatment of the disease in patients who had progressed on or could not tolerate other therapies.
Approval for the new indication was based on an 846-patient clinical trial in which newly diagnosed Ph+ CP-CML patients were treated with nilotinib or imatinib (Gleevec). The surrogate endpoint for a major molecular response was a significant reduction in the number of circulating CML cells at 12 months.
Roughly 44% of patients in the nilotinib group showed a response compared with 22% on imatinib
Go to Medpage Today/Therapy For Rare Leukemia to read more. Feel good and keep smiling! Pat & Pattie